Champions Oncology (CSBR) Enterprise Value (2011 - 2026)

Champions Oncology (CSBR) has 16 years of Enterprise Value data on file, last reported at $70.8 million in Q3 2026.

• On a quarterly basis, Enterprise Value fell 7.91% year-over-year to $70.8 million in Q3 2026; TTM through Jul 2026 was $70.8 million, a 7.91% decrease from a year earlier, with the FY2026 full-year figure at $78.0 million, down 12.06% from the prior year.
• Enterprise Value for Q3 2026 stood at $70.8 million, down from $78.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at $147.4 million in Q1 2025 and bottomed at $44.1 million in Q1 2023.
• Historically, Enterprise Value has averaged $80.7 million across 5 years, with a median of $78.0 million in 2026.
• The widest annual swing landed in 2023, when Enterprise Value plunged 55.79%; it then surged 97.94% in 2025.
• Year by year, Enterprise Value stood at $83.3 million in 2022, then retreated by 17.49% to $68.7 million in 2023, then declined by 26.05% to $50.8 million in 2024, then jumped by 70.3% to $86.5 million in 2025, then dropped by 18.21% to $70.8 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $70.8 million in Q3 2026, $78.0 million in Q2 2026, and $94.5 million in Q1 2026.